CVS earnings analysis
What we found in CVS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
CVS delivered a strong Q2 turnaround: revenue reached $106.096B, GAAP operating income rose 97.5% to $4.703B, and GAAP diluted EPS was $2.31. The primary driver was a sharp Health Care Benefits recovery, with a 250-bp improvement in MBR and $1.118B of adjusted operating-income growth, supplemented by Health Services growth and retail prescription-volume gains. Offsetting considerations are the 19.7% decline in commercial premium revenue, lower membership following the exchange exit, continuing PBM pricing pressure, and elevated medical utilization.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and EPS accelerated
- Q2 revenue rose $7.181B, or 7.3% YoY, to $106.096B and increased $6.246B from Q1 2026 revenue of $99.850B. GAAP diluted EPS was $2.31, up from $0.80 in Q2 2025 and $2.30 in Q1 2026.
- Material margin recovery
- Operating income nearly doubled to $4.703B, up $2.322B or 97.5% YoY; operating margin expanded to 4.43% from 2.41% a year ago and 4.1% in Q1 2026. Gross margin was 14.84%, above 13.3% in Q2 2025, though below 15.1% in Q1 2026.
- Insurance profitability improved
- Health Care Benefits adjusted operating income increased $1.118B, or 85.5%, to $2.426B as its medical benefit ratio improved 250 bps to 87.4%. Segment revenue grew $1.280B, or 3.5%, to $37.538B.
- Health Services delivered double-digit growth
- Health Services revenue increased $5.342B, or 11.5%, to $51.795B, led by $2.966B of mail and specialty revenue growth. Adjusted operating income rose $158M, or 10.0%, to $1.733B.
- Retail pharmacy volume remained strong
- Retail prescription volume rose 4.3% to 457.0M prescriptions, while Pharmacy & Consumer Wellness adjusted operating income rose $137M, or 10.2%, to $1.475B. Pharmacy same-store sales increased 2.9%.
- Operating cash flow and liquidity strengthened
- Six-month operating cash flow rose $4.141B, or 64.2%, to $10.594B. CVS ended June 30 with approximately $11.3B of cash and cash equivalents, including approximately $2.7B held by the parent or nonrestricted subsidiaries.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Commercial revenue and membership contracted
- Commercial premium revenue declined $1.629B, or 19.7%, to $6.625B, partly reflecting the 2026 exit from the individual exchange business. Total medical membership fell about 698,000 year over year to 26.023M.
- PBM pricing pressure constrains margins
- Health Services adjusted operating margin declined 10 bps to 3.3% despite revenue growth of 11.5%; management cited continuing pharmacy-client price improvements as a partial offset to improved purchasing economics.
- Corporate investment spending increased losses
- Corporate/Other adjusted operating loss widened $64M, or 15.5%, to $477M in Q2, driven by increased business investments. For the first half, the adjusted loss expanded $311M to $1.054B.
- Elevated utilization could reverse MBR gains
- Management states utilization remained elevated in Q2 2026, following a 250-bp MBR improvement to 87.4%; utilization beyond current levels could pressure Health Care Benefits and health-care-delivery results in 2026.
- No risk-factor update; capital deployment remains cautious
- No material risk-factor changes were reported versus the 2025 Form 10-K. Nevertheless, CVS had $11.500B of remaining repurchase authorization but repurchased $0 during Q2, preserving capital amid debt and operating priorities.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $2.31
- Gross margin
- 14.84%
- Operating margin
- 4.43%
- Segment
- Health Care Benefits revenue: $37.538B (+3.5% YoY)
- Segment
- Health Services revenue: $51.795B (+11.5% YoY)
- Segment
- Pharmacy & Consumer Wellness revenue: $33.816B (+0.7% YoY)
- Segment
- Corporate/Other revenue: $147M (+53.1% YoY)
What they said about what is next.
The 10-Q does not provide quantitative full-year guidance; quantitative outlook was provided separately in the earnings release/call.
The filing reads better than the one before it.
What came before.
- 10-Q · May 6, 2026
- CVS Health reported Q1 2026 revenues of $100.4 billion and an EPS of $2.30, both above consensus estimates of $94.9 billion in revenue and $2.21 in EPS. The company raised its full-year GAAP EPS guidance from a range of…
- 10-K · February 10, 2026
- CVS Health Corporation's 10-K filing for 2025 reveals a comprehensive review of their operational and financial health, highlighting a strategic pivot to enhance integrated health services and address challenges…
- 10-Q · October 29, 2025
- CVS Health Corporation reported a total revenue of $102.87 billion for Q3 2025, marking a 7.8% increase from Q3 2024. However, the company posted a net loss of $3.98 billion, primarily due to a significant $5.7 billion…
- 10-Q · July 31, 2025
- CVS Health's Q2 2025 results showed a substantial increase in revenue, surpassing prior estimates and last year's figures, though net income fell sharply due to litigation costs. The Health Care Benefits segment…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CVS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever